As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $175.5 million, which the Company believes will be sufficient to fund operations into the second half of 2026.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IKNA:
- Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
- Ikena Oncology, Inc. (IKNA) Q4 Earnings Cheat Sheet
- Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
- iKena Oncology CMO Sergio Santillana resigns, Caroline Germa succeeds
- Ikena Oncology Announces Leadership Change and Strategic Shift